FORM PTO-1449 (Modified)			Attorney Docket No.: 15280-368200US   Application No.: 09/508,552			0.: 09/508,552	
	ENTS AND PUE		Applicant: Jay A. Berzofsky et al.				
FOR APPLICANT'S INFORMATION			Filing Date: March 9, 2000		Group: Unassigned		
DISCLOSURE STATEMENT (Use several sheets if necessary)					1648		
Pafarance Designation Aug 2 4 2000 W			S. PATENT DOCUMENTS		RECEIVED Page 1		
Examiner	Document	Zuu Sate	Name	Class	Sub <sub>v</sub> class	Filing Date	
Initial	NOTENT . TO	DEMARKE			AUG 2 3 2005	/	
	- 0 181				TECH CENTER 1600/2	Appropriate)	
AA	4,629,783	12/16/86	Cosand	530		2900	
AB	4,943,628	07/24/90	Rosen et al.	530	326		
AC	5,030,449	07/09/91	Berzofsky et al.	424	88		
AD	5,081,226	01/14/92	Berzofsky et al.	530	324		
			EIGN PATENT DOCUM		T		
	Document No.	Date	Country	Class	Sub-class	Translation (Yes/No)	
AE	WO 87/07616	12/17/87	PCT	C07K			
AF	0 273 716	12/23/87	EP	C07K			
_/AG	WO / 94/26785	11/24/94	PCT	C07K			
OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
AH	Ahlers et al., "Construction of an HIV-1 Peptide Vaccine Containing a Multideterminant Helper Peptide Linked to a V3 Loop Peptide 18 Inducing Strong Neutralizing Antibody Responses in Mice of Multiple MHC Haplotypes after Two Immunizations," J. Immunol. 150:5647-5665, 1993  Ahlers et al., "Candidate HIV Type 1 Multideterminant Cluster Peptide-P18MN Vaccine Constructs Elicit Type 1 Helper T Cells, Cytotoxic T Cells, and Neutralizing Antibody, all Using the Same Adjuvant Immunization," AIDS Res. Hum. Retroviruses 12:259-272, 1996						
AJ	Ahlers et al., "Cytokine-in-Adjuvant Steering of the Immune Response Phenotype to HIV-1 Vaccine Constructs," J. Immunol. 158:3947-3958, 1997						
AK	Ahlers et al., "Enhanced Immunogenicity of HIV-1 Vaccine Construct by Modification of the native Peptide Sequence," Proc. Natl. Acad. Sci. USA 94:10856-10861, 1997						
AL	Belyakov, et al., "Mucosal Immunization with HIV-1 Peptide Vaccine Induces Mucosal and Systemic Cytotoxic T Lymphocytes and Protective Immunity in Mice Against Intrarectal Recombinant HIV-Vaccinia Challenge," Proc. Nat. Acad. Sci. 95:1709-1714, 1998						
AM	Berzofsky et al., "Construction of Peptides Encompassing Multideterminant Clusters of Human Immunodeficiency Virus Envelope to Induce <i>In Vitro</i> T Cell Responses in Mice and Humans of Multiple MHC Types," J. Clinical Invest. 88:876-884, 1991						
AN	Berzofsky and Berkower, "Novel Approaches to Peptide and Engineered Protein Vaccines for HIB Using Defined Epitopes: Advances in 1994-1995," <u>AIDS 1995 9(A)</u> :S143-S157, 1995						
AO	Bomsel, M., "Transcytosis of Infectious Human Immunodeficiency Virus Across a Tight Human Epithelial Cell Line Barrier," Nature Medicine 3:42-47, 1997						
AP	Butini et al., "Comparative Analysis of HIV-Specific CTL Activity in Lymphoid Tissue and Peripheral Blood," J. Cellular Biochemistry Abstract Supplement: 147, 1994						
AQ	Cranage et al., "Macaques Infected with Live Attenuated SIVmac are Protected Against Superinfection via the Rectal Muosa," Virology 229:143-154, 1997						
EXAMINER	Jullin XI	lucker	DATE CONSIDERED	7/17/02			
V.				7 7			

-	449 (Modified) ENTS AND PUBLICATIONS	Attorney Docket No.: 15280-368200US   Application No.: 09/508,552   Applicant: Jay A. Berzofsky et al.				
FOR APPLICA	ANT'S INFORMATION	Filing Date: March 9, 2000	Group Unasabled			
	E STATEMENT (Use several	1 111119 2010. 171111111 7, 2000	Group: Unas Parce E/VED			
sheets if neces		Control Control And Indian in Marinel	C distant HAUS 2Nove in			
THE STATE OF THE S		of Antigen-Specific Antibodies in Vaginal oxin as a Mucosal Adjuvant," Infection and				
3 M AS	V	nogenicity and Adjuvanticity of site-directe				
	toxin," <u>Infection and Immunity</u>		7590 <b>0</b>			
AT &		Cytotoxic T Lymphocyte Memory in Muco	osal Tissues After Mucosal but			
TRADEMENT	<del> </del>	<u>. Exp. Med. 184</u> :1879-1890, 1996				
		S Vaccines," New England Journal of Med	<del></del>			
AV		minant Regions in the Human Immunodeficem of Major Histocompatibility Complex R				
AW	Haynes, B.F., "Scientific and Science 260:1279-1286, 1993	ocial Issues of Human Immunodeficiency	Virus Vaccine Development,"			
AX	Klavinskis et al., "Mucosal or Targeted Lymph Node Immunization of Macaques with a Particulate SIVp27 Protein Elicits Virus-Specific CTL in the Genito-Rectal Mucosa and Draining Lymph Nodes," <u>J. Immunol.</u> 157:2521-2527, 1996					
AY		otensin-1 Converting Enzyme Activity Prod 160 Peptide for Presentation by Major Histo 1417- 1422, 1992				
AZ	<u>7</u> :12-18, 1996	ches to Mucosal Immunization," Seminars	· · · · · · · · · · · · · · · · · · ·			
BA	Lehner, et al., "Protective Mucosal Immunity Elicited by Targeted Iliac Lymph Node Immunization with a Subunit SIV Envelope and Core Vaccine in Macaques," <u>Nature Medicine</u> 2:767-775, 1996					
BB	Heterosexual Transmission of I	Transmission of Simian Immunodeficiency Human Immunodeficiency Virus," <u>J. Virol</u>	<u>. 63</u> :4277-4284, 1989			
BC		sisted Analysis of Envelope Protein Sequences: Prediction of Antigenic Epitopes in Co				
BD	Musey et al., "HIV-1 Induces C 185:293-300, 1997	Cytotoxic T Lymphocytes in the Cervix of I	Infected Women," J. Exp. Med.			
BE	Neutra et al., "Antigen Samplin Responses," <u>Annu. Rev. Immu</u>	ng Across Epithelial Barriers and Induction nol. 14:275-300, 1996	of Mucosal Immune			
BF	Parditos et al., "Antibody Responses to Non-Immunogenic Synthetic Peptides Induced by Co-Immunization with Immunogenic Peptides," <u>Immunology</u> 77:262-266, 1992					
BG	Parditos et al., "Mucosal Immunization with a Measles Virus CTL Epitope Encapsulated in Biodegradable PLG Microparticles," <u>J. Immun. Meth.</u> 195:135-138, 1996					
ВН		Effect of a Non-Toxic Mutant of Heat-Labi les Virus-Specific CTL Responses After Intogy 89:483-487, 1996				
l_BI		nunization with CTL Epitope Peptides from kin Induces Peptide-Specific CTLs and Prounol. 158:834-841, 1997				
EXAMINER	1 Thinks	DATE CONSIDERED 7/17/02				

FORM PTO-1449 (Modified)		Attorney Docket No.: 15280-368200US	Application No.: 09/508,552		
LIST OF PATENTS AND PUBLICATIONS		Applicant: Jay A. Berzofsky et al.			
1		Filing Date: March 9, 2000	Group: Unassigned		
· · · · · · · · · · · · · · · · · · ·					
BJ	Shirai et al., "Broad Recognitio				
2000	Shirai et al., "Helper-Cytotoxic T Lymphocyte (CTL) Determinant Linkage Required for Priming of Anti-HIV CD8+ CTL in Vivo with Peptide Vaccine Constructs," J. Immunol. 152:549-556, 1994				
JENT & TRADE	Takahashi et al., "An Immunodominant Epitope of the Human Immunodeficiency Virus Envelope Glycoprotein Gp160 Recognized by Class I Major Histocompatibility Complex Molecule-Restricted Murine Cytotoxic T Lymphocytes," <a href="Proc. Natl. Acad. Sci. USA">Proc. Natl. Acad. Sci. USA</a> 85:3105-3109, 1988				
ВМ	Takahashi et al., "Induction of Broadly Cross-Reactive Cytotoxic T Cells Recognizing an HIV-1 Envelope Determinant," Science 255:333-336, 1992				
BN	Takeshita et al., "Molecular Analysis of the Same HIV Peptide Functionally Binding to Both a Class I and a Class II MHC Molecule," <u>J. Immunol.</u> 154:1973-1986, 1995				
ВО	Yamamoto et al., "Mutants in the ADP-ribosyltransferase Cleft of Cholera Toxin Lack Diarrheagenicity but retain adjuvanticity," J. Exp. Med. 185:1203-1210, 1997				
BP	Yamamoto et al., "A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity," Proc. Natl. Acad. Sci. USA 94:5267-5272, 1997				
EXAMINER Jun 1/17/02					
	LIST OF PATIFOR APPLICATION OF PATIFOR APPLICATION OF PATIFOR APPLICATION OF PATIFORM OF P	LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)  BJ Shirai et al., "Broad Recognition Multiple Class I Histocompatible Shirai et al., "Helper-Cytotoxic Anti-HIV CD8+ CTL in Vivo von Murine Cytotoxic T Lymphocy Murine Cytotoxic T Lymphocy Murine Cytotoxic T Lymphocy Murine Cytotoxic T Lymphocy Murine Determinant," Science BN Takeshita et al., "Induction of Envelope Determinant," Science BN Takeshita et al., "Molecular An and a Class II MHC Molecule,"  BO Yamamoto et al., "Mutants in the but retain adjuvanticity," J. Exp.  BP Yamamoto et al., "A nontoxic in immunity," Proc. Natl. Acad. S.	Applicant: Jay A. Berzofsky et al.  FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)  BJ Shirai et al., "Broad Recognition of Cytotoxic T Cell Epitopes from the HI Multiple Class I Histocompatibility Molecules," J. Immunol. 148:1657-16  Shirai et al., "Helper-Cytotoxic T Lymphocyte (CTL) Determinant Linkag Anti-HIV CD8+ CTL in Vivo with Peptide Vaccine Constructs," J. Immunoder Glycoprotein Gp160 Recognized by Class I Major Histocompatibility Con Murine Cytotoxic T Lymphocytes," Proc. Natl. Acad. Sci. USA 85:3105-  BM Takahashi et al., "Induction of Broadly Cross-Reactive Cytotoxic T Cells Envelope Determinant," Science 255:333-336, 1992  BN Takeshita et al., "Molecular Analysis of the Same HIV Peptide Functional and a Class II MHC Molecule," J. Immunol. 154:1973-1986, 1995  BO Yamamoto et al., "Mutants in the ADP-ribosyltransferase Cleft of Cholera but retain adjuvanticity," J. Exp. Med. 185:1203-1210, 1997  Yamamoto et al., "A nontoxic mutant of cholera toxin elicits Th2-type resimmunity," Proc. Natl. Acad. Sci. USA 94:5267-5272, 1997		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.